ClinicalTrials.gg
Sign In
CompletedNCT05298826Updated Mar 28, 2022

Recombinant Factor VII for Intractable Postpartum Haemorrhage

An observational study in Post Partum Hemorrhage, sponsored by Aljazeera Hospital. Completed at 1 site in Egypt. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2022-03-28.

Sponsored by Aljazeera Hospital · Observational

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
41
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

Postpartum haemorrhage remains at the top of the causes of maternal deaths in both developed and developing countries .

Read the detailed description

Major postpartum haemorrhage is a dangerous complication that accounts for the highest maternal morbidity rate

02

Conditions studied

  • Post Partum Hemorrhage

Browse trials for

03

In context

Postpartum Hemorrhage

469 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.

This study's enrollment of 41 is below the median of 169 across 96 observational studies indexed under Postpartum Hemorrhage.

Browse Postpartum Hemorrhage studies →

Lead sponsor

Aljazeera Hospital is the lead sponsor of 64 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

women who has resistant postpartum hemorage

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women with severe resistant postpartum hemorage

Exclusion criteria

Exclusion Criteria:

  • women without postpartum hemorage
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
41 participants (actual)
Patient registry
No

Groups and cohorts

  • Junior staff has started the management and called for the senior staff.

    Drug: recombinant factor VIIa

  • senior staff. managed the case from the start

    Drug: recombinant factor VIIa

Interventions

06

What researchers measure

Primary outcomes

  1. The number of women who had hysterectomy

    number of women resistant to the treatment and needed hysterectomy

    Time frame: 24 hours

07

Study locations

1 site
  • Doaaa Alaa
    Cairo, Egypt
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in Jan 2020, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2022
First posted
Mar 28, 2022
StartActual
Jun 1, 2019
Primary completionActual
Jan 1, 2020
CompletionActual
Jan 10, 2020
Last update
Mar 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05298826
Lead sponsor
Aljazeera Hospital
Responsible party
Sponsor
First posted
Mar 28, 2022
Start date
Jun 1, 2019
Primary completion
Jan 1, 2020
Completion
Jan 10, 2020
Last update
Mar 28, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Postpartum Hemorrhage →

Other studies from this sponsor

Aljazeera Hospital

Start the discussion